1. Home
  2. CRAI vs DBVT Comparison

CRAI vs DBVT Comparison

Compare CRAI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRA International Inc.

CRAI

CRA International Inc.

HOLD

Current Price

$161.79

Market Cap

1.1B

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$19.13

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRAI
DBVT
Founded
1965
2002
Country
United States
France
Employees
N/A
90
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
CRAI
DBVT
Price
$161.79
$19.13
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$245.00
$32.04
AVG Volume (30 Days)
148.8K
186.2K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
1.48%
N/A
EPS Growth
20.77
10.26
EPS
8.14
N/A
Revenue
$751,583,000.00
$5,636,000.00
Revenue This Year
$7.82
$35.04
Revenue Next Year
$5.14
$2,360.78
P/E Ratio
$19.97
N/A
Revenue Growth
9.33
35.77
52 Week Low
$142.53
$7.53
52 Week High
$227.29
$26.19

Technical Indicators

Market Signals
Indicator
CRAI
DBVT
Relative Strength Index (RSI) 56.11 42.35
Support Level $152.81 $18.88
Resistance Level $167.66 $23.52
Average True Range (ATR) 6.04 0.83
MACD 0.98 -0.08
Stochastic Oscillator 82.70 10.78

Price Performance

Historical Comparison
CRAI
DBVT

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: